Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma
Daniel J. Olson(University of Chicago), Jason J. Luke(UPMC Hillman Cancer Center)
Cited by 220
Related Papers
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
|Journal for ImmunoTherapy of Cancer|2016|510
Tumor cell p38 inhibition to overcome immunotherapy resistance
|Research Square|2023|5